On July 13, the National Joint Drug Procurement Office announced the preliminary result for the bid of the 7th round of volume-based procurement (VBP). 327 products (60 types drugs if differentiated by the type and content ratio of active ingredient) owned by 217 companies won the bid in the preliminary stage.1
The bid-winning products cover 31 disease categories, including common and/or chronic diseases such as hypertension, diabetes, gastrointestinal disorders and severe diseases of lung/liver/kidney/colon cancer.
The bid-winning products' prices reduced by 48% on average. In terms of kidney cancer drugs, the average price of Lenvatinib Mesilate Capsules was cut by 83.33% from 108 yuan/capsule to 18 yuan/capsule. Among drugs for treating high-blood pressure, Nifedipine Controlled-release Tablets' average price dropped by 58% and Metoprolol Succinate Sustained-Release Tablets' by 53%.
In the 327 products, 6 are from international pharm companies and their VBP prices are listed below.
Oseltamivir Phosphate Capsules
75mg*10 capsules per blister pack in each box
Hetero Labs Limited
100ml: 37g(I)*10 bottles in each box
Shanghai Bracco Sine Pharmaceutical Industry Co., Ltd.
10mg*10 tablets per blister pack in each box
Almirall, S.A. (Industrias Farmaceuticas Almirall, S.A.)
10mg*30 tablets in each box
Sandoz Inc. (Lek Pharmaceuticals d.d.)
Micafungin Sodium for Injection
50mg*1 bottle in each box
Astellas Pharma Europe B.V. (Astellas Pharma Tech Co., Ltd. Takaoka Plant)
Tigecycline for Injection
50mg*10 phials in each box
Pfizer Europe MA EEIG (Wyeth Lederle
Since 2018, China National Healthcare Security Administration (NHSA) has organized 7 rounds of VBPs which cover 294 types of drugs. According to the estimation based on pre-VBP prices, drugs in the VBPs account for 35% of the chemical drugs and biological products procured by public medical institutions.
Articles on Previous VBPs: